NasdaqCM - Nasdaq Real Time Price USD

Genprex, Inc. (GNPX)

Compare
0.4286 +0.0466 (+12.20%)
As of 12:27 PM EDT. Market Open.
Loading Chart for GNPX
DELL
  • Previous Close 0.3820
  • Open 0.4000
  • Bid 0.4210 x 100
  • Ask 0.4286 x 100
  • Day's Range 0.3900 - 0.4290
  • 52 Week Range 0.2810 - 16.9600
  • Volume 616,588
  • Avg. Volume 428,809
  • Market Cap (intraday) 1.109M
  • Beta (5Y Monthly) -0.57
  • PE Ratio (TTM) --
  • EPS (TTM) -15.6000
  • Earnings Date Nov 12, 2024 - Nov 18, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 8.75

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

www.genprex.com

21

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GNPX

View More

Performance Overview: GNPX

Trailing total returns as of 9/23/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

GNPX
95.34%
S&P 500
19.79%

1-Year Return

GNPX
97.24%
S&P 500
32.26%

3-Year Return

GNPX
99.63%
S&P 500
29.98%

5-Year Return

GNPX
98.78%
S&P 500
90.96%

Compare To: GNPX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GNPX

View More

Valuation Measures

Annual
As of 9/20/2024
  • Market Cap

    988.82k

  • Enterprise Value

    -1.47M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.23

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    0.18

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -145.94%

  • Return on Equity (ttm)

    -318.88%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -26.14M

  • Diluted EPS (ttm)

    -15.6000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.46M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -12.45M

Research Analysis: GNPX

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

7.50
8.75 Average
0.4286 Current
10.00 High
 

Company Insights: GNPX

People Also Watch